TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27692497
Drug: PHMB-based solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHMB-based solution
Study: 10704160
Drug: Nitroglycerin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin plus Heparin
Study: 8263618
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium tocolysis
Study: 3518729
Drug: Treuphadol oblong
Normalized name: Cydonia oblonga leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treuphadol oblong tablets (500 mg paracetamol)
Study: 3518729
Drug: Treuphadol Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treuphadol Plus oblong tablets (500 mg paracetamol, 30 mg codeine phosphate)
Study: 3518729
Drug: Treuphadol suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treuphadol suppositories (750 mg paracetamol)
Study: 3518729
Drug: Commercial tablets
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial tablets (500 mg paracetamol)
Study: 26091965
Drug: DHA-enriched formula
Normalized name: STRESS FORMULA 500,BIOTIN ENRICHED TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-enriched formula (600 mg daily)
Study: 25517706
Drug: Nicotine-replacement therapy
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine-replacement therapy for 8 weeks
Study: 12800126
Drug: Nicotine-replacement therapy
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine-replacement therapy
Study: 17490963
Drug: Diet containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet containing 550 mg choline x 70 kg(‐1) x d(‐1) for 10 d followed by <50 mg choline x 70 kg(‐1) x d(‐1)
Study: 17490963
Drug: Diet containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet containing 550 mg choline x 70 kg(‐1) x d(‐1)
Study: 17490963
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplement (400 microg/d)
Study: 11079284
Drug: Sumatriptan tablets
Normalized name: Sumatriptan Tablets
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sumatriptan tablets
Study: 1305042
Drug: Ukrain administered
Normalized name: Ukrain cation
DrugBank: Ukrain cation (DB17150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ukrain administered intramuscularly (i.m.) or intravenously (i.v.) every one, two or three days in doses of 5 to 50 mg for 7 to 40 days
Study: 1305042
Drug: Ukrain administered
Normalized name: Ukrain cation
DrugBank: Ukrain cation (DB17150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ukrain administered for three years in the dose of 5 to 50 mg/injection in repeated courses
Study: 28759833
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E treatment for 8 weeks
Study: 23764683
Drug: Famotidine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (100 mg twice daily, n = 16)
Study: 21840734
Drug: Maximal dose
Normalized name: Spirulina maxima preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal dose of fluvastatin (80 mg/day)
Study: 21840734
Drug: Titrated dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated dosing of fluvastatin (starting at 20 mg/day)
Study: 19640855
Drug: Health promotion
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health promotion programme consisting of three sessions weekly over 12 weeks (one educational session and two physical activity sessions).
Study: 10701034
Drug: Anaesthetist-administered midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Anaesthetist-administered midazolam
Study: 8989196
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion (3.0 to 20 micrograms/kg/min)
Study: 22520536
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg and Ezetimibe 10 mg
Study: 18299307
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine mixed with rapid-acting insulin analog, administered twice daily
Study: 18299307
Drug: Neutral protamine
Normalized name: Neutral protamine hagedorn insulin
DrugBank: Neutral Protamine Hagedorn (NPH) insulin (DB18001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral protamine Hagedorn (NPH) therapy with rapid-acting insulin analog, administered twice daily
Study: 16781218
Drug: Clopidogrel plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel plus aspirin (ASA)
Study: 7978599
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg IV naloxone
Study: 7978599
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg IV naloxone
Study: 2689916
Drug: Buflomedil chlorhydrate
Normalized name: buflomedil
DrugBank: Buflomedil (DB13510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buflomedil chlorhydrate (150 mg intravenous injection in bolus)
Study: 25219982
Drug: Retina Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retina Implant Alpha IMS
Study: 23860295
Drug: Short-acting β2‐agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting β2‐agonist (SABA) - 20 µg of inhaled procaterol
Study: 19398092
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg estradiol and 400 mg progesterone
Study: 19398092
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg estradiol and 400 mg progesterone
Study: 19398092
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg estradiol and placebo
Study: 12413372
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (abciximab and half-dose reteplase)
Study: 12413372
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of reteplase
Study: 9844098
Drug: Moderate exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate exercise (30-minute sessions of weight-bearing physical education lessons three times weekly for 8 months)
Study: 7536619
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy for cystic fibrosis, details on dosage and duration not available
Study: 7536619
Drug: Current treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current treatments for cystic fibrosis, details on specific treatments not available
Study: 2574049
Drug: xamoterol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: xamoterol (200 mg twice a day)
Study: 6993253
Drug: Inhaler with
Normalized name: albuterol 90 MCG /INHAL Dry Powder Inhaler with sensor, 200 Actuations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaler with a 32 X 100 mm tube actuated 2 seconds before inhalation
Study: 28835058
Drug: Dexmedetomidine 1
Normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 μg/kg intravenously after general anesthesia induction
Study: 28835058
Drug: Lidocaine cream
Normalized name: Neomycin and Polymyxin B Sulfates and Lidocaine Cream
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine cream with endotracheal tube
Study: 28835058
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dexmedetomidine with lidocaine cream
Study: 19246310
Drug: Fentanyl (1.6‐1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (1.6‐1.8 mg) plus tropisetron (5 mg/100 ml)
Study: 19246310
Drug: Fentanyl (0.8‐1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (0.8‐1.0 mg) and flurbiprofen axetil (200 mg) plus tropisetron (5 mg/100 ml)
Study: 14631327
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus metformin 1000 mg twice a day
Study: 10847226
Drug: Progesterone cream
Normalized name: NATURAL PROGESTERONE CREAM,TOP
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone cream 40 mg daily
Study: 10847226
Drug: Progesterone cream
Normalized name: NATURAL PROGESTERONE CREAM,TOP
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone cream 20 mg, twice daily
Study: 10847226
Drug: Progesterone cream
Normalized name: NATURAL PROGESTERONE CREAM,TOP
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone cream (both regimens)
Study: 2065637
Drug: Zinc supplement
Normalized name: Zinc supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplement (22.5 mg daily)
Study: 6343572
Drug: Indomethacin with
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin with usual medical therapy
Study: 6343572
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with usual medical therapy
Study: 6343572
Drug: Indomethacin only
Normalized name: Indomethacin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin only if usual therapy failed (strategy 2)
Study: 6343572
Drug: Indomethacin with
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin with initial medical therapy (strategy 1)
Study: 16038246
Drug: Mw vaccine
Normalized name: polyethyloxazoline (200000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mw vaccine (1 x 10^9 heat killed bacilli for the first dose, 5 x 10^8 for the second dose, given 6 months apart)
Study: 16038246
Drug: Mw vaccine
Normalized name: polyethyloxazoline (200000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mw vaccine (when both patients and contacts received the vaccine)
Study: 16038246
Drug: Mw vaccine
Normalized name: polyethyloxazoline (200000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mw vaccine (when only patients received the vaccine)
Study: 16038246
Drug: Placebo (1/8th
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1/8th dose of normal dose of tetanus toxoid)
Study: 11929147
Drug: Measured creatinine
Normalized name: Creatinine
DrugBank: Creatinine (DB11846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measured creatinine excretion (CrExcr)
Study: 10336576
Drug: Sibrafiban 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibrafiban 2 mg
Study: 10336576
Drug: Sibrafiban 5-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibrafiban 5-12 mg
Study: 10336576
Drug: Sibrafiban 5-7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibrafiban 5-7 mg
Study: 10336576
Drug: Sibrafiban 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibrafiban 12 mg
Study: 7482386
Drug: benazepril 10
Normalized name: benazepril 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: benazepril 10 mg (BZ 10)
Study: 7482386
Drug: benazepril 5
Normalized name: benazepril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: benazepril 5 mg/hydrochlorothiazide 6.25 mg (BZ + HCTZ)
Study: 1963134
Drug: Different drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different drugs for reducing occlusion frequency after coronary artery bypass
Study: 6440658
Drug: Bacampicillin 4.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacampicillin 4.8 g with probenecid 1 g
Study: 6440658
Drug: Amoxycillin 3
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 3 g with probenecid 1 g
Study: 18635912
Drug: Kampo (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kampo (combination of ginseng, oriental bezoar, and glycyrrhiza)
Study: 16847795
Drug: Subcutaneous terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous terbutaline while maintaining oxytocin infusion
Study: 16847795
Drug: Oxytocin discontinuation
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin discontinuation
Study: 16847795
Drug: Subcutaneous terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous terbutaline and oxytocin
Study: 14565653
Drug: DVP (daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DVP (daunorubicin 45 mg/m2 daily, days 1, 2 and 3; prednisone 60 mg/m2 daily orally days 1‐35; vincristine 2 mg intravenously on days 1, 8, 15 and 22)
Study: 14565653
Drug: DATVP (daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DATVP (daunorubicin 60 mg/m2 daily, days 1, 2 and 3; cytarabine 25 mg/m2 intravenous bolus followed by 200 mg/m2 daily as a continuous infusion on days 1‐5; 6-thioguanine 100 mg/m2 orally every 12 h on days 1‐5; vincristine 2 mg intravenously on days 1 and 8; prednisone 60 mg/m2/day orally, days 1‐7)
Study: 11083681
Drug: Albuterol (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (800 microg)
Study: 22302887
Drug: Caffeine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (500 mg test dose)
Study: 22302887
Drug: Caffeine metabolism
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine metabolism rate
Study: 27761556
Drug: Propofol/alfentanil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol/alfentanil (10 µg/kg IV alfentanil)
Study: 27761556
Drug: Propofol/ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol/ketamine (0.5 mg/kg IV ketamine)
Study: 24976448
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of rosuvastatin 10 mg with metformin 750 mg
Study: 24976448
Drug: Monoadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoadministration of rosuvastatin 10 mg
Study: 24976448
Drug: Monoadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoadministration of metformin 750 mg
Study: 24976448
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (rosuvastatin, metformin, and coadministration)
Study: 22212240
Drug: Melatonin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (6 mg administered 30 min prior to exercise)
Study: 20707767
Drug: Solifenacin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin (5 or 10 mg/day, flexibly dosed)
Study: 402275
Drug: Phentolamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentolamine infusion during surgery with glucose load (20 g)
Study: 402275
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's lactate solution infusion during surgery with glucose load (20 g)
Study: 402275
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's lactate solution and phentolamine infusion during surgery (control group)
Study: 21792057
Drug: Topical cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporine A (0.05%) twice a day plus preservative-free artificial tears four times a day for 4 months
Study: 19327530
Drug: Diazoxide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazoxide (100 micromol/L)
Study: 1563054
Drug: Nasal prongs
Normalized name: SET,INFUSION,5-PRONG BAXTER #L5C4446
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal prongs (Group NP, 4 L.min‐1)
Study: 1563054
Drug: Simple facemask
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple facemask (Group FM, 8 L.min‐1)
Study: 30135030
Drug: Etifoxine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etifoxine (100 mg)
Study: 24773915
Drug: Topical cream
Normalized name: Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cream delivering narrow-band ultraviolet B, average of 38 sessions
Study: 20353858
Drug: Collagenase injection
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Collagenase injection for MCP joint contracture
Study: 20353858
Drug: Collagenase injection
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Collagenase injection for PIP joint contracture
Study: 20353858
Drug: Initial response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial response to collagenase injection
Study: 18561583
Drug: Solubilized BPO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solubilized BPO 5% gel
Study: 18561583
Drug: BPO 5%/clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPO 5%/clindamycin 1% combination product
Study: 14759375
Drug: Low-dose alteplase
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose alteplase (50 mg) and tirofiban (0.4 microg/kg/min/30 minute bolus; infusion of 0.1 microg/kg/minute)
Study: 14759375
Drug: Standard strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard strategy with either full-dose alteplase (100 mg) or stenting PCI
Study: 7688432
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg pentosanpolysulfate 3 times per day
Study: 3523457
Drug: Ceftazidime (CZ)
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime (CZ) at a dose of 150 mg/kg/day divided every 8 hours
Study: 3523457
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with chloramphenicol and ampicillin (CA)
Study: 29316962
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard care with antibiotics and chlorhexidine mouthwash)
Study: 18417739
Drug: Tipifarnib administered
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tipifarnib administered concurrently with radiation therapy at dose levels ranging from 100 to 150 mg/m(2)/dose, followed by adjuvant tipifarnib at 200 mg/m(2)/dose for 21 consecutive days in 28-day cycles.
Study: 15923005
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral feeding (8 h)
Study: 15923005
Drug: Delayed oral
Normalized name: lipase 12,000 UNT / amylase 39,000 UNT / protease 39,000 UNT Delayed Oral Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed oral feeding (24 h)
Study: 12534646
Drug: Amprenavir 600
Normalized name: Lexiva (as fosamprenavir calcium) 700 MG (amprenavir 600 MG) Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amprenavir 600 mg twice a day for 10 days
Study: 12534646
Drug: Delavirdine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delavirdine 600 mg twice a day for 10 days
Study: 11244724
Drug: Amantadine hydrochloride
Normalized name: Amantadine Hydrochloride
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amantadine hydrochloride 100 mg/d
Study: 11244724
Drug: Control (ordinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (ordinary medication only)
Study: 9253881
Drug: Mebendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole (400 mg single dose)
Study: 21666432
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg/d) for 6 months
Study: 19725485
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection with lidocaine
Study: 15056486
Drug: Atypical antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotic treatment over 14 weeks
Study: 15056486
Drug: Atypical antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotic treatment
Study: 2820626
Drug: CGS 14824A
Normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS 14824A (2 mg p.o. q.d.)
Study: 2820626
Drug: CGS 14824A
Normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS 14824A (10 mg p.o. q.d.)
Study: 27435610
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (transcutaneous electrical stimulation)
Study: 27435610
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (transcutaneous electrical stimulation) in mild-to-moderate OSA subgroup
Study: 17853277
Drug: Quetiapine 300
Normalized name: quetiapine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine 300 mg/day and 600 mg/day
Study: 16027809
Drug: Preparation of
Normalized name: kit for the preparation of Ga-68
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation of polyunsaturated phospholipids (lipostabil forte)
Study: 10466877
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg daily for 10 days)
Study: 442014
Drug: D‐ASA (Dipyridamole
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐ASA (Dipyridamole 30 mg and ASA 300 mg administered intravenously two hours before surgery, then orally three times a day in tablets containing dipyridamole 50 mg and ASA 330 mg)
Study: 442014
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of Heparin (5000 IU subcutaneously twice a day starting two hours pre-operatively)
Study: 11710409
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate (0.5 g x kg(-1) body mass)
Study: 11710409
Drug: NaCl (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl (0.1 g x kg(-1) body mass)
Study: 9205017
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg, titrated to 20 mg if needed
Study: 9205017
Drug: Simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 10 mg, titrated to 20 mg if needed
Study: 30334639
Drug: Verinurad 5
Normalized name: Verinurad
DrugBank: Verinurad (DB11873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verinurad 5 mg
Study: 30334639
Drug: Verinurad 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verinurad 12.5 mg
Study: 29688628
Drug: Verinurad 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verinurad 2.5 mg
Study: 21831359
Drug: Paliperidone ER
Normalized name: Paliperidone ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone ER Medium (3 mg)